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Abstract
Assays for the detection of the iron regulatory hormone hepcidin in plasma or urine have not yet been widely available, 
whereas quantitative comparisons between hepcidin levels in these different matrices were thus far even impossible due to 
technical restrictions. To circumvent these limitations, we here describe several advances in time-of flight mass 
spectrometry (TOF MS), the most important of which concerned spiking of a synthetic hepcidin analogue as internal 
standard into serum and urine samples. This serves both as a control for experimental variation, such as recovery and 
matrix-dependent ionization and ion suppression, and at the same time allows value assignment to the measured hepcidin 
peak intensities. The assay improvements were clinically evaluated using samples from various patients groups and its 
relevance was further underscored by the significant correlation of serum hepcidin levels with serum iron indices in healthy 
individuals. Most importantly, this approach allowed kinetic studies as illustrated by the paired analyses of serum and urine 
samples, showing that more than 97% of the freely filtered serum hepcidin can be reabsorbed in the kidney. Thus, the here 
reported advances in TOF MS-based hepcidin measurements represent critical steps in the accurate quantification of 
hepcidin in various body fluids and pave the way for clinical studies on the kinetic behavior of hepcidin in both healthy and 
diseased states.
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Introduction
Protein profiling by time-of flight mass spectrometry (TOF MS) is 
based on polypeptide enrichment by selective binding to a 
(bio)chemical surface prior to T O F  MS of retained proteins and 
peptides [1]. This technique is widely used to address several 
biomedical questions in the proteomics field, e.g. for the discovery of 
disease related biomarkers in biological fluids [2,3] for protein 
interaction studies [4] and for immunoproteomics-based approach­
es [5-7]. Furthermore, T O F  MS-based assays have the potential to 
simultaneously distinguish and quantify multiple isoforms/variants 
of a particular protein/peptide in contrast to most ELISA-based 
assays [5,8-11]. In  all these application areas, reliable quantification 
is imperative. Clinical mass spectrometry assays optimally use 
internal standards to correct for recovery, variable ionization and 
suppression of the molecule under analysis [12,13].
Hepcidin is a 25-amino acid peptide that is synthesized in 
hepatocytes and secreted in the plasma. It binds to the cellular iron 
export channel ferroportin and causes its internalization and 
degradation [14] thereby decreasing iron efflux from enterocytes 
and macrophages into plasma reviewed in ref [15-17]. Increased iron 
stores and inflammation induce hepcidin synthesis, whereas suppres­
sion occurs during hypoxia and increased and /o r ineffective 
erythropoiesis. Furthermore, hepcidin deficiency plays a central role 
in the iron loading in hereditary hemochromatosis and thalassemia’s.
Notwithstanding recent progress, much work remains in 
defining the role of hepcidin in both healthy and diseased states. 
However, to date, few investigative tools are available [15-17]. 
The development of immunochemical methods based on the 
production of specific hepcidin antibodies is difficult due to the 
small size of hepcidin (25 amino acids; hepcidin-25 [hepc25]), and 
its conservation among animal species, complicating the elicitation 
of an immune response in host species. To date, mainly the 
antibody-based dotblot assay described by Nemeth et al. has 
successfully been used to (semi) quantify hepcidin in urine [18-21]. 
However, due to its quite laborious procedure, and its unsuitability 
for serum, this assay is not optimal for measurements in large 
clinical studies. By means of surface enhanced laser desorption/ 
ionisation (SELDI-)TOF MS technology, we and others were 
successful to semi-quantify hepcidin and its isoforms in urine and 
serum [9,10,22,23]. Very recently, other serum hepcidin assays 
were reported that exploited liquid chromatography tandem mass 
spectrometry (LC-M S/M S [24,25]). After protein precipitation 
and peptide extraction, a mixture of serum and internal standard 
could be analyzed by LC-M S/M S. The use of non-hepcidin 
related peptides as internal standard, however, may affect the 
accuracy and reproducibility of the hepcidin concentration levels.
Here, we describe an update of the T O F MS hepcidin method 
for both serum and urine with considerable improvements on 
sensitivity, reproducibility, value assignment and quantitative
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abilities. This facilitates the exchangeability of studies performed 
by the few other available methods to date and provides the long 
sought tool to study hepcidin kinetics.
Results
To overcome several of the technical limitations that previously 
interfered with the robustness of hepcidin measurements by T O F 
MS, we have systematically reconsidered all analytical steps and 
made improvements wherever possible. This experimental survey 
and the subsequent evaluation of the improvements are described 
below, whereas technical details can be found in the Material & 
Methods section.
Recovery
Relatively large sample volumes (500 mL) obtained by dilution 
of the samples prior to sample preparation resulted in higher 
hepcidin peaks compared to our previously reported procedure in 
which samples were in a much smaller (5 mL) final volume [10]. 
This increased recovery of hepcidin is likely ascribed to decreased 
sticking of hepcidin with the increase of the (sample volume)/(tube 
surface) ratio or to less aggregation with the decrease of the 
hepcidin concentration. This updated procedure improved
considerably the sensitivity of the method for the detection of 
hepc25 (see below).
Oxidation
In some urinary samples the methionine residue of hepc24 
(2673.9 Da) and hepc25 (2789.4 Da) were prone to oxidation (to 
[D ]TH FPICIFCCG CCH RSK CG M -O xCCK T, 2689.9 Da and
2805.4 Da, respectively) at experimental conditions [26]. This 
ambient ozone induced oxidation artifact was minimized by 
carrying out sample preparation in a nitrogen atmosphere by the 
use of an incubator with a nitrogen inlet. Oxidation peaks of 
hepcidin in the MS spectra were completely absent in urine 
samples prepared under these conditions, whereas they were 
clearly visible in some spectra of samples loaded on the arrays in 
ambient air (Figure 1A). In our hands methionine oxidation of 
serum hepcidin was never observed.
Standard curves
Standard curves of the internal standard hepc24 were 
constructed by serially diluting hepc24 (0-20 nM) in tubes with 
blank urine and serum to an end volume of 500 mL, immediately 
applied to IM AC-Cu2+ Chips and processed according to protocol 
and measured by MS. Linear standard curves were obtained for
F igure  1. SELDI-TOF MS p ro file s  o b ta in e d  in  th e  d iffe re n t experim en ts . SELDI-TOF MS profiles o f (A) hepidin-24 spiked urine sample 
showing next to the expected hepcidin forms also methionine oxidized (Ox) forms o f Hepc24 and Hepc25; (B and C) different patient sera and urines, 
respectively, spiked with Hepc24 (5 nM into urines and 10 nM into sera). Note, the influence of the serum and urine matrices on the peak height of 
the Hepc24 spiked to patient samples; (D and E), blank serum and urine samples spiked with both Hepc24 and Hepc25 (7.5 nM of both hepcidin 
forms into urine and 10 nM into serum). Note that the method appears to be more sensitive for Hepc25 than for Hepc24, w ith an average peak 
intensity ratio Hepc24/Hepc25 of 0.693. This is probably due to the absence of a negatively charged aspartic acid residue in Hepc24, which negatively 
affects its binding on the IMAC-Cu2+ protein chip surface. The hepcidin isoforms Hepc20, Hepc22 (only in urine), Hepc24 (synthetic analogue) and 
Hepc25 are indicated by arrows. 
doi:10.1371/journal.pone.0002706.g001
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hepc24 in blank urine (y = 8.62x—0.49; R  =0.996) and blank 
serum (y = 4.90x+3.97; R 2 = 0.994).
Matrix influences
To detect possible matrix influences on the flying behavior in 
the mass spectrometer, hepc24 was added to diverse urine and 
serum samples from our collection that have been shown to 
contain various concentrations of endogenous hepc25 [10]. We 
found that when spiked with the same hepc24 concentration, 
hepc24 peak intensities were lower for serum compared to urine. 
This indicates that the protein-rich serum matrix suppresses the 
hepcidin signal, possibly by a high competition for binding sites on 
the chip surface. Furthermore, we observed that the recovery of 
hepc24 also differs between individual serum or urine samples 
(Figure 1B and C), which may be attributed to distinct matrix- 
dependent hepcidin ionization efficiencies.
Hepc24/hepc25 ratio
As we aimed to base our quantitative hepc25 concentration 
measurement on the level of the hepc25 peak intensity relative to 
that of hepc24, we set out to determine the hepc24/hepc25 
intensity ratio’s in blank urine and serum samples, that were all 
spiked with both compounds in duplicates of 5 different 
concentration combinations (Figure 1D and E). Results revealed 
no influence of the internal standard hepc24 to the peak height 
and position of the hum an hepc25, making a competition between 
hepcidin 24 and 25 for binding to the chip and ionization unlikely. 
Notably, the IM AC-Cu + method appears to be more sensitive for 
the hepc25 than for the hepc24 analogue, with mean (SD) peak 
ratio’s hepc24/hepc25 of 0.709 (0.058, n = 1 0 ) for serum, and 
0.678 (0.071, n =  10) for urine, with an average of 0.693 (0.066, 
n = 20) for both body fluids. The observation of similar ratio’s for 
both urine and serum matrices, however, suggests that the 
intensity ratio is specimen independent.
Reproducibility
Intra-chip or spot-to spot variation of hepc25 measured for the 
urine application ranged from 6.1% at 3.2 nM  to 7.3% at 1.2 nM 
(n = 8). Similarly, precision was also good for the serum 
application with a CV of 5.7% at the higher level (4.4 nM, 
n = 8) and 11.7% at the lower level (1.8 nM, n = 8). Comparison of 
these CV’s (average value of 7.7%) with a CV of around 12% 
obtained previously without internal standard [10] indicates that 
the use of an internal standard improved precision of the hepc25 
assay, mainly by its ability to correct for differences in spot quality 
and instrumental settings.
Lower level of detection (LLOD)
Based on the measured background noise in each MS spectrum 
(see Figure 2), the calculated LLOD values of the improved 
SELDI-TOF MS assay varied between 0.003-0.037 nM /m m ol 
creat for urine samples. This detection limit appeared to be lower 
than that reported by Nemeth et al. [20] with a detection limit of 
0.43 nM /m m ol creat (10 ng /m g  creat; Table 1). Remarkably, for 
serum samples the LLOD ranged from 0.55 and 1.55 nM, which 
is a significant improvement from the approximate 22 nM 
described for our previous procedures [10] and that of 16 nM 
reported by Tomosugi et al [22] in a similar procedure. 
Furthermore, it is within the range of the detection limits of
0.3-1.8 nM  (1-5 ng/m l) described recently by M urphy et al. [24] 
and M urao et al. [25] using more laborious LC-M S/M S 
procedures (Table 1).
F igure  2. E ffect o f  th e  use o f  an in te rn a l s tandard  on  th e  
hepc id in -25  concen tra tions  in  u rine  and serum  o f selected 
c lin ica l p o p u la tio n s . Hepc25 concentrations were calculated in nM 
based on the known concentration of spiked hepc24 in serum (A) and 
urine (B) samples. For serum, hepc24 intensities were corrected for the 
background intensity o f unspiked samples (hepc24-bl). Note that for 
both urine and serum specimens the LLOD depends on the individual 
sample matrix and therefore varies between samples. The LLOD was 
determined in the 25 human serum and urine samples by using the 
background intensities at m/z 2400, 2515, 2846 for serum and at m/z 
2299, 2510, 2910, for urine samples, respectively. The detection limit 
was defined as the mean+2 SD of these measurements and found be 
2.0 peak intensity for serum and 1.76 peak intensity for urine. The lower 
level o f detection (LLOD) in nM of each individual sample was 
determined by incorporating the sample specific hepc24 peak intensity 
value and these mean LLOD values in peak int for hepc25 peak at 
2789 m/z in the formulas 1 and 2 for urine and serum (see Material and 
Methods section). Ctrl, control; LPS, volunteers injected with polysac­
charide (6 h after injection); IDA, iron deficiency anemia; TM, 
thalassemia major in various stages of disease; HH, C282Y homozygous 
hereditary hemochromatosis patients of various stages of disease; O, 
hepcidin concentration; * ,  sample specific LLOD, the hepcidin 
concentration of the sample is then<LLOD. 
doi:10.1371/journal.pone.0002706.g002
Clinical evaluation in patient groups
After clinical diagnosis we categorized urine and serum sample 
pairs from previous studies [9,10,19,27] into 5 clinical groups of 5 
patient each and quantified the hepc25 levels after spiking of hepc24 
as internal standard. Urine and serum hepcidin values of the
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Table 1. Comparison of hepcidin results between recent studies.
M ethod SELDI SELDI LC/MS-MS Im m unodot
reference this report Tom osugi [22] M urphy [24] Nem eth [18,20,21]
urine n nM/mmol creat' n nM/mmol creat' n n nM/mmol creat'
LLOD 0.00S-0.0S7* n.d. n.d n.p. 0.4S
controls 5 0.21-2.14 n.d. n.d. 105 0.4S-8.54
IDA 5 <0.011-0.045 n.d. n.d. ±2 ±0.21-030
inflammation 5 2.6S-11.8 n.a. n.d. ±8 ±2.56-S4.1
serum n nM' nM" nM'
LLOD 0.55-1.55# 16 0.36 n.d.
controls5 5 <1.04-6.18 n.a. 10 <0.36-16.3 n.d.
IDA 5 <0.71-<1.S8 n.d. n.d n.d.
Inflammation 5 12.1-51.4 n.a. n.d. n.d.
Data are presented in ranges as data from the current study do not allow calculation o f means and SD's and the raw data o f previous studies are only partially available. 
LLOD; Lower lim it o f detection; n.d., not determined; n.a., not applicable; n.p., not provided.
*exact value depend on the individual urine and the creatinine concentration.
# exact value depend on the individual serum.
conversion factors: nM to  mg is 2.789; from nM/mmol creat to ng/mg creat is 23.44.
$in a rigorously defined group o f healthy controls (see Table 2) these figures are: n = 23, range 0.86-12.43 nM. 
doi:1Q.1371/journal.pone.QQQ27Q6.tQQ1
individual patients correlated significantly (p = 0.783, p  = 0.002). 
Figure 2 illustrates the urine and serum hepc25 levels for the 
different categories of patients. In fact, the urine and serum hepcidin 
values in the (small) patient groups increased progressively from 
IDA to inflammation, with intermediate values in controls that 
differ from both patients with IDA (serum p = 0.10, urine p = 0.009) 
and inflammation (serum p = 0.009, urine p = 0.009) (Table 1 and 
Figure 2). Note that the hepcidin values of thalassemia and 
hemochromatosis patients are not particular informative because of 
individual differences in extent of anemia and treatment. The 
hepcidin concentration ranges we found for the patient groups are 
comparable to the scarce data reported by a few other groups 
(Table 1 [18,20-22,24]. Nevertheless, international inter-laboratory 
comparisons ofaccuracy and precision ofthe hepcidin assays in well 
defined and larger samples of patients with the various methods 
available to date, are warranted to increase insight and exchange­
ability of the hepcidin results between studies (analogous as 
performed previously for non-transferrin-bound-iron [28]).
Correlation with serum iron indices in healthy control 
subjects
We evaluated the serum assay by correlating the serum hepcidin 
levels with various serum iron indices in 23 volunteers. Sample 
characteristics are presented in Table 2. Hb, serum ferritin, and 
body iron levels were significantly higher for the males than for the 
females, whereas serum iron, transferrin saturation (TS), soluble 
transferrin receptor (sTfR) and hepcidin levels were similar for 
both sexes. Within the strict selection criteria adopted, serum 
ferritin levels in these subjects are anticipated to represent a 
reliable measure of body iron [29], especially when considering a 
formula that includes the levels of serum transferrin receptor [30]. 
Indeed, serum hepcidin levels correlated significantly with both 
ferritin and estimated body iron stores in the total group and in 
men (Figure 3; Table 3). For women this was only significant for 
body iron stores. These findings are in agreement with previous 
findings on the increase of hum an hepcidin synthesis by iron stores 
[18,22,31,32] and thereby demonstrate the usefulness of the 
hepcidin assay in clinical studies.
Fractional excretion of hepcidin
As shown in Table 1, value assignment in the current study 
shows for the first time that the urine and serum hepcidin levels 
appear to be of a similar magnitude. This suggests that after 
filtration, hepcidin is almost completely reabsorbed by the 
proximal tubulus, similarly to other small proteins, such as P2- 
microglobulin. In fact, estimation of the fractional excretions of 
hepcidin from urine-serum control pair samples resulted in a 
values between 0-3% , pointing towards a 97% to a nearly 100% 
tubular reabsorption of the freely filtered serum hepcidin (Table 4).
Discussion
In this study we have described an updated T O F  MS method 
for both serum and urine hepcidin with considerable improve­
ments on sensitivity, reproducibility, value assignment and, 
importantly, quantitative abilities which are critical to allow the 
exchangeability of studies performed by the few other available 
methods and to study hepcidin kinetics. O ur data clearly 
demonstrate the added value of hepc24 as an internal standard 
for mass spectrometry as it, once spiked to a sample, controls for 
the variation in hepc25 outcome due to differences i) in peptide 
recovery during sample preparation, ii) changes in ProteinChip 
quality, iii) variable ionization and ion suppression, and iv) changes 
in instrumental performance of the mass spectrometer (this study; 
our unpublished observations).
A notable finding was the fact that hepc24 and hepc25 showed 
different binding characteristics when IM AC-Cu2+ chips were 
used as selective surface for protein binding. Possibly, binding of 
hepc24 is impaired because it lacks the amino-terminal aspargine 
residue of hepc25 (Material & Methods), which may affect metal 
affinity of hepcidin [33]. In this study, however, we decided to 
continue measurements with IM AC-Cu2+ chips to allow compar­
ison with previous work [10] by multiplying the concentration 
obtained by equation 1 and 2 (Material & Methods) with the 
hepc24/hepc25 ratio as a constant. Importantly, our recent 
analyses showed that cation exchange-based enrichment of 
hepcidin yielded a hepc24/hepc25 ratio of 1 (data not shown), 
which implies that both peptides have similar binding character­
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Table 2. Characteristics of healthy control subjects.
All Males Females P
Data are means w ith 95% C.I. and p-values o f males vs females by t-test. TS, transferrin saturation; sTfR, soluble transferrin receptor.
Body iron stores were calculated on the basis o f the logarithm o f the concentrations in micrograms o f serum transferrin receptor/serum ferritin (TfR/ferritin ratio) and 
expressed as milligram per kilogram body weight, as follows: body iron (mg/kg) = — [log(TfR/Ferritin ratio) —2.8229]/0.1207 [30]. Positive values represent the iron 
surplus in stores, while negative values represent iron deficit in tissues. 
doi:10.1371/journal.pone.0002706.t002
istics at this surface. This clearly underscores that the specific 
recovery of hepcidin is dependent on the employed chromato­
graphic chemistry for protein binding. Therefore, we strongly 
recommend controlling for the hepc24/hepc25 ratio on a regular 
basis by incorporating hepc24/hepc25 spiked blanks in future 
(updated) measurement protocols.
The most valuable feature of the updated hepcidin assay is the 
fact that the combination of selective protein binding with sensitive 
mass detection is uniquely capable of accurate quantification of 
hepcidin in both serum and urine (see Table 1). Importantly, 
inclusion of the internal hepc24 standard corrects for urine/blood 
matrix-differences, which up till now strongly affected the measured 
hepcidin peak intensities. This allowed for the first time the 
calculation of the fractional excretion of hepcidin, which appeared 
to be <3%  in the analyzed serum /urine pairs. Thus, these advances 
have paved the way for large (pre)-clinical studies to investigate 
tubular reabsorption of hepcidin in various clinical disorders,
3
°  1
0  ~l i---------------------1---------------------1---------------------1
0 1 2  3 4
log hepcidin
F igure  3. C o rre la tio n  be tw een  serum  hepc id in  and fe rr it in .
Serum hepcidin levels in 23 healthy volunteers (Table 2), as determined 
by our updated MS method, were correlated with their ferritin levels. 
Values were log transformed prior to correlation analysis. Pearson 
correlation: 0.6804 (p =  0.0004). 
doi:10.1371/journal.pone.0002706.g003
especially in anemias that are associated with renal diseases where 
hepcidin is predicted to be an important contributor [34].
From a clinical standpoint, the availability of an accurate 
quantitative evaluation of serum hepcidin represents a substantial 
progress. Previous reports casted doubts on the reliability of
Table 3. Correlation of serum hepcidin levels with iron 
indices in controls with rigorously defined normal iron status.
Iron indices All Males Females
Hb 0.08 —0.44 0.01
iron 0.1S 0.1S 0.S7
TS (%) 0.40 0.52 0.42
ferritin 0.68** 0.76** 0.57
sTfR —0.25 —0.27 — 0.45
Body iron 0.72** 0.78** 0.65*
Data are correlation coefficients by Pearson correlation. STfR, soluble transferrin 
receptor; TS, transferrin saturation. Hepcidin and ferritin values were log 
transformed prior to  correlation analysis *:P<0.05; **: P<0.01. 
doi:10.1371/journal.pone.0002706.t003
Table 4. Fractional excretion of hepcidin.
Disease n fractional excretion (%) sample
1 2 3
Ctrl S 1.0 2.S 0.6
LPS 1 2.0 n.a. n.a
TM S 0.1 1.0 1.2
HH S 2.8 2.9 1.6
The fractional excretion (FE) is calculated by: urine hepcidin (nM)xserum creat 
(mM) x100/serum hepcidin (nM) xurine creat (mM) x1000. n, the number o f pairs 
for which all data needed to  calculate the FE were available. Ctrl, controls; LPS, 
volunteers injected with polysaccharide (6 h after injection); TM, thalassemia 
major in various stages o f disease; HH, C282Y homozygous hereditary 
hemochromatosis patients at various stages o f disease; tubular reabsorbtion 
(%) = 100- FE (%).
doi:10.1S71/journal.pone.0002706.t004
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determining hepcidin in serum, since it did not correlate well with 
either clinical diagnosis or laboratory markers of iron metabolism 
[35]. Several explanations for these unexpected discrepancies were 
postulated, including a possible too rapid clearance of this small 
peptide from circulation, suggesting urinary hepcidin (normalized 
to glomerular filtration) as a better estimate of hepcidin production 
than single-point assay in serum. The data obtained with the 
present updated quantitative method, provide evidence for both 
good correlation with iron indices in appropriate controls (Table 3), 
and proper detection of peptide variations for diagnostic purposes 
(Figure 2). This indicates that we may have now reached a 
sufficient level of analytic sensitivity to make that the serum 
hepcidin measurements can now be used as a tool in clinical 
studies
Altogether, this study shows the potential of high-throughput 
T O F  MS-based diagnostic assays, especially in the case of small 
peptides that are difficult to handle in ELISA-based immunological 
approaches. Importantly, MS can provide additional information 
on post translational modifications, as exemplified by the discrim­
ination between the hepc20, -22, an d /o r -25 isoforms in serum and 
urine. ‘‘However, it goes without saying that several scientific 
questions have to be addressed and further assay improvements 
should be established before hepcidin measurements can be 
implemented in general clinical laboratories. These issues comprise, 
but are not limited to, standardization, mass resolution, healthy 
reference values, correspondence serum and urine hepcidin, 
influence of potential hepcidin carrier proteins, cross-assay 
validation, which are all subject of our ongoing investigations. 
Nevertheless, we anticipate that the here described and further 
advances in T O F  MS-based approaches can be instantaneously 
implemented in dedicated laboratories to quantify hepcidin levels in 
a broad range of biological specimens and thereby will be valuable 
to further unravel the role of this peptide hormone in health and 
disease. In this respect, it may be appreciated that future updates of 
our quantitative T O F  MS hepcidin assay will be posted on the 
website “www.hepcidinanalysis.com” .
Materials and Methods
Patient samples
Study participants consisted of subjects that were randomly 
selected from our sample collection described previously [10], and 
additional volunteers with normal iron parameters. Participants of 
our previous study included 25 urine-serum sample pairs from 5 
healthy volunteers (laboratory personnel and some of their 
spouses), 5 hereditary hemochromatosis (HFE C282Y-homozy- 
gous) patients (various stage of phlebotomy), 5 iron deficiency 
anemia patients, and 5 thalassemia patients treated with chelation 
therapy. The patients were recruited by their physicians during 
outpatient clinic visits (all in the Radboud University Nijmegen 
Medical Centre, Nijmegen, the Netherlands, except for the 
thalassemia major patients, who were in Ospedale Sant’Eugenio, 
Rome, Italy). Endotoxemia samples (n = 5) from volunteers were 
obtained as previously described [19]. Hepcidin blank sera and 
urines were obtained from a patient with juvenile hemochroma­
tosis due to a novel hemojuvelin mutation that was shown to have 
hepcidin levels below the detection limit of the method [36].
Twenty-three additional controls (12 men and 11 women) with 
strictly normal iron status were enrolled in Verona as previously 
described [23]. Briefly, they were selected among healthy 
volunteers participating in a phase II trial at the Centre for 
Clinical Research of the Azienda Ospedaliero-Universitaria di 
Verona, Italy. At enrollment, they completed a questionnaire with 
specific items relevant to iron metabolism (i.e. any history of blood
donations, previous pregnancy, menstrual losses, etc.) and were 
evaluated by laboratory studies including complete blood count 
(CBC), serum iron, transferrin saturation, ferritin, C-Reactive 
Protein, soluble Transferrin Receptor (sTfR), liver function tests, 
and creatinine. To be considered as appropriate ‘‘normal 
controls’’ for the hepcidin assay by SELDI-TOF-MS, all these 
parameters were required to be normal.
W ritten informed consent was obtained from all study 
participants, according to the Declaration of Helsinki. Samples 
were collected between December 2005 and June 2007 and stored 
at —80°C in aliquots to avoid multiple freeze-thaw cycles. 
Hepcidin assays for the current study have been performed 
between January and July 2007.
SELDI-TOF MS measurements
Hepcidin measurements by SELDI-TOF-M S were performed 
as previously described [10] and updated with i) the use of an 
internal standard to allow quantification and value assignments to 
urine and serum hepcidin levels, and ii) exploiting a working 
volume of 500 mL instead of 20 mL to increase recovery of 
hepcidin during sample preparation. In brief, after dissolving the 
lyophilized peptide hepcidin 24 (hepc24) in distilled water 
(0.5 mM), 5 mL or 10 mL of the solution was added as an internal 
standard to 495 mL urine (5 nM) or 490 mL serum sample 
(10 nM), respectively. The feasibility of this procedure was 
illustrated by application of a 5 ml-sample to copper-loaded 
immobilized metal-affinity capture ProteinChip arrays 
(IMAC30-Cu2+) that binds hepcidin based on its affinity for 
Cu2+ ions. However, also weak cation exchange bead-based 
approaches were successfully employed to capture hepcidin 
(iso)forms based on their isoelectric point > 8  to allow hepcidin 
measurements by matrix assisted (MA)LDI T O F  MS [10, 37], (our 
unpublished observations) . All binding surfaces were equilibrated 
and washed with appropriate buffers according to the manufac­
tures instructions (Bio-Rad, Hercules, CA). Subsequent work up, 
SELDI-TOF MS instrumental settings, read out and data analysis 
are described elsewhere [10], with the addition that protein chip 
handling was performed in a nitrogen atmosphere to prevent 
methionine oxidation [26]. In previous studies, proteomic 
techniques showed that hepc25, hepc22 and hepc20 were present 
in urine, whereas only hepc25 and hepc20 were present in serum 
[10]. Samples with hepc25 peak heights > 55  Int were considered 
to be out of the linear range and were diluted with blank serum or 
urine from a patient with juvenile hemochromatosis [36].
Internal standard
We choose to include an internal standard in our mass 
spectrometry method as this enables to: i) increase the precision, 
ii) improve the accuracy by reducing matrix influences and to 
control for instrumental settings and, iii) assign a value to hepcidin 
concentration. As internal standard we selected hepc24 for the 
following reasons: i) T O F  MS can clearly distinguish it’s molecular 
weight from the endogenous hum an hepcidin isoforms hepc25, 
hepc22 and hepc20, ii) it has similar chromatographic binding and 
flying characteristics as the natural hepcidin isoforms and iii) its m /z  
position in urine and serum SELDI-profiles is in a region with 
relatively few other peaks; e.g. in contrast to the heavy isotopes of 
hepc25, hepc24 has a mass that is different from that of methionine 
oxidized hepc25. In our experiments we used synthetic human 
hepc24 (TH FPICIFCCG CCH RSK CGM CCK T, 2673.9 Da, 
weight assessment by quantitative amino acid analysis in triplicate) 
and human hepc25 (D THFPICIFCCGCCHRSK CG M CCKT,
2789.4 Da) that were obtained from Peptides International 
Incorporated (Louisville, KY). Noteworthy, hepc24 differs from
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the most abundant endogenous hepcidin form hepc25 by the 
absence of the amino-terminal aspargine (D) residue, whereas the 
natural occurring hepc22 and hepc20 isoforms lack the amino- 
terminal sequences D T H  and DTHFP, respectively.
This experimental set up enabled us to assign values to urine 
(normalized to urinary creatinine values and reported in n M / 
mmol creatinine [creat]) and serum hepc25 (nM), which were 
formerly expressed as M int/m m ol creat and M int/L , respectively 
[10]. For this purpose the following equations were applied for 
urine (1) and serum (2):
1. [(sample 2789 m /z  peak intensity) x5 nM /(hepc24 spiked 
sample 2673 m /z  peak intensity)]/mmol creat
2. (sample 2789 m /z  peak intensity) x 10 nM /(hepc24 spiked 
sample 2673 m /z  peak in ten sity - non spiked sam ple 
2673 m /z  peak intensity)
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